Demand for U.S. Life Sciences Real Estate Strengthens in Q4
Economic Growth, Job Expansion, and Drug Development Drive Sector Optimism for 2025
The U.S. life sciences real estate market experienced positive net absorption in the fourth quarter of 2024, indicating a steady rebound despite a rise in vacancy rates due to new construction completions. According to CBRE’s latest quarterly report, the vacancy rate reached 19.7% as significant new lab spaces entered the market.
Leasing activity for lab spaces showed a strong uptick, totaling 3.4 million sq. ft. in Q4—an increase of 28% year-over-year. Net absorption reached 920,000 sq. ft., marking the third gain in the past five quarters. This steady demand is fueled by record-high employment in life sciences, multiple drug approvals, and a substantial 19% increase in venture capital funding, which totaled $30.4 billion in 2024.
Despite the heightened vacancy rate caused by pandemic-era construction projects, the pipeline of new developments is beginning to slow. At the end of Q4, 12.1 million sq. ft. of lab space was under construction—significantly down from peak levels in 2024, suggesting a more balanced supply-demand dynamic ahead.
San Diego and Key Market Trends
San Diego emerged as one of the top-performing life sciences markets in Q4, alongside the San Francisco Bay Area, with strong leasing activity and positive net absorption. Overall, 10 of the 13 largest U.S. life sciences markets posted gains, reflecting broad industry resilience.
2025 Market Outlook
Looking ahead, CBRE’s 2025 U.S. Life Sciences Outlook highlights key factors that will influence market performance this year. The report points to an improving economy, robust sector employment, and a more favorable investment climate as positive drivers for life sciences real estate.
However, challenges remain. Approximately 8 million sq. ft. of new lab space is projected for completion in 2025, which will likely contribute to increased vacancy rates, particularly in leading hubs like Boston, San Francisco, and San Diego. Despite these concerns, economic conditions and investment trends indicate a more stable environment for life sciences companies and real estate stakeholders.
“The life sciences sector operates on longer cycles than the real estate market due to the complexities of drug development and commercialization,” said Matt Gardner, CBRE’s Americas Life Sciences Leader. “That said, macroeconomic trends are pointing to improved conditions for life sciences real estate in 2025.”
As San Diego continues to be a key player in the life sciences industry, its strong fundamentals and sustained demand position it well for long-term growth. Market participants should closely monitor economic and investment trends to capitalize on opportunities in the evolving real estate landscape